{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:00Z","timestamp":1794048900477,"version":"4.8.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005407","name":"Food and Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jhep.2021.11.024","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:58:07Z","timestamp":1652702287000},"page":"1249-1262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":281,"title":["How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace L.H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-6845","authenticated-orcid":false,"given":"Anna S.F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.11.024_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.11.024_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Website: https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/. Accessed on 20 April\u00a02021."},{"key":"10.1016\/j.jhep.2021.11.024_bib4","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","author":"Cornberg","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.11.024_bib7","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","article-title":"Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study","volume":"69","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.11.024_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2021.11.024_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","article-title":"Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection","volume":"69","author":"Caviglia","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib11","first-page":"61A","article-title":"Novel anti-HBV therapies using CRISPR\/cas9 targeting HBV genome strongly suppress HBV","volume":"72","author":"Murai","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib14","first-page":"19A","article-title":"Long term nucleos(t)ide analogue therapy reduced the extent of HBV DNA integration in chronic hepatitis B patients","volume":"72","author":"Chow","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib15","first-page":"13A","article-title":"Tenofovir disoproxil\u00a0fumarate treatment reduces the number of transcriptionally active viral integrations in chronically infected HBV patients","volume":"17","author":"Hsu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib16","first-page":"S284","article-title":"VALIANT: a targeted long-read approach to study translocation and mRNA isoforms associated with HBV integration","volume":"75","author":"Soulette","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2021.11.024_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrgastro.2017.185","article-title":"Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?","volume":"15","author":"Cornberg","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.11.024_bib20","first-page":"105","article-title":"The role of HBsAg levels in the current management of chronic HBV infection","volume":"27","author":"Honer Zu Siederdissen","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2021.11.024_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Lebosse","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.11.024_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.13150","article-title":"Effects of pegylated interferon-alpha based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"26","author":"Ren","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.11.024_bib24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B Be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","volume":"68","author":"Yip","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2021.11.024_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/liv.14330","article-title":"The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B","volume":"40","author":"Wong","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.11.024_bib31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib32","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.11.024_bib33","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0168-8278(20)30755-8","article-title":"Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop-NUC trial (LBO06)","volume":"73","author":"van Bommel","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib34","first-page":"19A","article-title":"HBsAg loss is higher among Caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multiethnic cohort of patients with chronic hepatitis b (RETRECT-B study)","volume":"72","author":"Hirode","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.11.024_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/17474124.2020.1738219","article-title":"Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B","volume":"14","author":"Hadziyannis","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.11.024_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2021.11.024_bib39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.11.024_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","author":"Lok","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib43","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S0168-8278(20)30773-X","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","volume":"73","author":"Janssen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib47","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/S0168-8278(20)30790-X","article-title":"Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib48","first-page":"S736","article-title":"Virologic response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib49","first-page":"S281","article-title":"Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor","volume":"75","author":"Mani","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib50","first-page":"S299","article-title":"Second generation Hepatitis B Virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities","volume":"75","author":"Dawei Cai","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib51","series-title":"Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158, September 01","year":"2021"},{"key":"10.1016\/j.jhep.2021.11.024_bib52","first-page":"521A","article-title":"Viral sequence analysis of chronic hepatitis B (CHB) patients treated with the capsid assembly modulator (CAM-N) JNJ-56136379 (JNJ-6379) as monotherapy in the JADE phase 2a study","volume":"72","author":"Verbinnen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib53","first-page":"LP32","article-title":"HBV RNAI inhibitor RG6346 in phase 1b-2a trial was safe, well tolerated, and resulted in substantial and durable reductions in serum HBsAg levels","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib54","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(20)30647-4","article-title":"Preliminary safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in chronic hepatitis B patients","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib55","first-page":"62A","article-title":"Safety and pharmacodynamics of the gal-Nac siRNA AB-729 in subjects with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib56","first-page":"435A","article-title":"Dose response with the RNA interference therapy JNJ-3989 combined with nucleos(t)ide analogue treatment in expanded cohorts of patients with chronic hepatitis B","volume":"70","author":"Gane","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib57","first-page":"S203","article-title":"Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression","volume":"75","author":"Yuen","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib58","first-page":"S761","article-title":"Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers","volume":"75","author":"Paratala","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib59","first-page":"S738","article-title":"Preliminary\u00a0on-treatment data from a Phase 2 study evaluating VIR-2218 in combination with pegIFN\u03b12a in patients with CHB","volume":"75","author":"Yuen","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib60","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(20)30646-2","article-title":"Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with ISIS 505358 in chronic hepatitis B (CHB) patients on stable nucleos(t)ide analogue (NA) regimen and in NA -naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib61","first-page":"63A","article-title":"Combination of antisense oligonucleotides (ASOs) ALG-020572 and ALG-020576 against hepatitis B virus (HBV) improves activity and can be combined with other anti-HBV agents","volume":"72","author":"Hong","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib62","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31855-X","article-title":"Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model","volume":"66","author":"Gilmore","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib63","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/S0168-8278(18)31226-1","article-title":"First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001","volume":"68","author":"Erken","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.11.024_bib65","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib66","doi-asserted-by":"crossref","first-page":"104853","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in\u00a0vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2021.11.024_bib67","first-page":"502A","article-title":"ALG-010133, a representative S-antigen transport-inhibiting oligonucleotide polymer (STOPS) effectively inhibits hepatitis B surface antigen (HBsAg) secretion in multiple hepatitis B virus (HBV) cell models","volume":"72","author":"Nie","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib68","first-page":"S741","article-title":"Safety, tolerability and pharmacokinetics (PK) of single and multiple doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOP) for the treatment of chronic hepatitis B","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib69","first-page":"S125","article-title":"Liver toxicity in the Phase 2 Catalyst 206 trial of inarigivir 400mg daily added to a nucleos(t)ide in HBeAg negative patients","volume":"73","author":"Agarwal","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib70","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S0618-8278(19)30084-2","article-title":"Ascending dose cohort study of inarigivir - a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial","volume":"70","author":"Yuen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib71","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib73","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.11.024_bib74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00430-014-0379-5","article-title":"Therapeutic vaccination and\u00a0immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck","volume":"204","author":"Kosinska","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhep.2021.11.024_bib75","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib76","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhep.2021.11.024_bib77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.11.024_bib78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib80","article-title":"The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified Vaccinia Ankara viral vectors; A novel therapeutic vaccine strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2021.11.024_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112754","article-title":"HBV immune-therapy: from molecular mechanisms to clinical applications","volume":"20","author":"Boni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2021.11.024_bib82","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.11.024_bib83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib84","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib86","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.11.024_bib87","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B","volume":"75","author":"Janssen","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib88","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2021.11.024_bib89","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib90","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garcia-Lopez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib91","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.11.024_bib92","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2021.11.024_bib93","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.11.024_bib94","first-page":"324","article-title":"3-year treatment of tenofovir alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"Hou","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821022339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821022339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:56Z","timestamp":1759175036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821022339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0168827821022339"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.11.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}